Co-Diagnostics Inc
NASDAQ:CODX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Co-Diagnostics Inc
NASDAQ:CODX
|
US |
|
Giglio Group SpA
MIL:GG
|
IT |
Co-Diagnostics Inc
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 101 full-time employees. The company went IPO on 2017-07-12. The firm is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. The company also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The firm uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 101 full-time employees. The company went IPO on 2017-07-12. The firm is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. The company also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The firm uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.
Revenue: Full-year 2025 revenue was $0.6 million, down from $3.9 million in 2024, as grant revenue fell and commercial activity stayed limited.
Losses: Net loss widened to $46.9 million, mainly because of an $18.9 million noncash impairment charge tied to in-process R&D intangible assets.
India progress: Co-Diagnostics said CoSara received a CDSCO license to manufacture the PCR Pro instrument in India and is preparing for local manufacturing and TB clinical work.
TB opportunity: Management highlighted India and the WHO’s updated TB guidance as a major near-term opportunity, and said it expects TB commercialization in India by the third quarter of '26.
COVID dropped: The company is moving its U.S. respiratory submission forward without COVID because COVID-positive samples were too scarce in the trial, though management said COVID could be added later.
Liquidity: Cash and marketable securities ended the year at $11.9 million, and management said it will keep evaluating financing options, including equity, debt, partnerships and grant funding.
